SAN CARLOS, Calif.--(BUSINESS WIRE)--May 10, 2006--Nektar Therapeutics (Nasdaq:NKTR - News) Highlights include approval of Exubera® (insulin human (rDNA origin)) Inhalation Powder in the U.S. and EU with first launch in Germany in mid-May; the filing for approval of two partner products with Nektar technology; and presentation of clinical data for Amphotericin B Inhalation Powder product.
